Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

X. Cynthia, Lisa A. Carey, Anna Weiss et al.|JAMA Oncology|2024

Cited by 20